Skip to content

Clinical and Metabolomic Study on Improving Ovarian Reserve Function by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Therapy

Clinical and Metabolomic Study on Improving Ovarian Reserve Function by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Therapy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002440
Enrollment
Unknown
Registered
2025-12-10
Start date
2024-11-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve

Interventions

Combined Therapy Group:Photodynamic therapy + Traditional Chinese Medicine (Dingkun Dan)
TCM Group:Dingkun Dan Therapy
Western Group:Photodynamic Therapy + Placebo (Dingkun Dan Simulant)

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Females (aged 25-40 years);2) Patients who meet the diagnostic criteria for TCM (Traditional Chinese Medicine) syndromes of kidney deficiency and imbalance between yin and yang of the kidney;3) Patients who meet the DOR diagnostic criteria

Exclusion criteria

Exclusion criteria: 1) Patients with organic lesions such as ovarian tumors, pituitary adenomas, endometrial tuberculosis, intrauterine adhesions or endometrial damage after induced abortion, as well as those with polycystic ovary syndrome, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, or thyroid dysfunction;2) Women with infertility who have received sex hormone therapy in the past 3 months;3) Patients with severe or unstable physical diseases, involving the liver, kidney, gastrointestinal, cardiovascular, respiratory, endocrine, neurological, immune, hematological, or neuropsychiatric systems;4) Patients with substance (alcohol or drug) abuse or dependence in the past 3 months; heavy smokers (those who smoke 20 or more cigarettes per day);5) Patients with a history of allergy to the study drug or photosensitivity, or with contraindications to Dingkun Dan;6) Patients who have participated in a clinical trial of another study drug within 1 month before being included in this study (first interview);7) Other conditions that may reduce the possibility of enrollment or complicate enrollment, as judged by the researcher, such as frequent changes in work environment which may easily lead to loss of follow-up.

Design outcomes

Primary

MeasureTime frame
Ovarian reserve function assessment indicators (AMH, AFC, FSH);

Secondary

MeasureTime frame
Biochemical indicators;Menstrual flow scale;Traditional Chinese Medicine symptom scale;Quality of life scale;

Countries

China

Contacts

Public ContactSun Aijun

Peking Union Medical College Hospital

saj@pumch.cn010-69158133

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026